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Autologous stem cell transplantation (ASCT) is indicated in a number of hematologic malignancies, including
multiple myeloma, non-Hodgkin lymphoma, and Hodgkin lymphoma. Relapse, however, remains 1 of the
main causes of post-ASCT failure, and several strategies are being investigated to decrease the risk of relapse
of progression. Recent advances in the treatment of hematological malignancies have included adoptive
transfer of genetically modiﬁed T cells that express chimeric antigen receptors or T cell receptors, as well the
use of checkpoint inhibitors. Early clinical results in nontransplantation patients have been very promising.
This review will focus on the use of gene-modiﬁed T cells and checkpoint inhibitors in stem cell
transplantation.
 2016 American Society for Blood and Marrow Transplantation.INTRODUCTION genetically modiﬁed T cells that express chimeric antigen
Autologous stem cell transplantation (ASCT) is indicated
in a number of hematologic malignancies, including multiple
myeloma (MM), non-Hodgkin lymphoma (NHL), and Hodg-
kin lymphoma (HL) [1-6]. Relapse, however, remains 1 of the
main causes of post-ASCT failure and several strategies are
being investigated to decrease the risk of relapse of pro-
gression. Furthermore, some patients may not be candidates
for ASCT because of inadequate response to salvage therapy.
Although the ongoing development of novel targeted
therapies impacts the actual indications for ASCT, there
remains a signiﬁcant unmet need for novel approaches to
improve disease control in the setting of ASCT. The beneﬁts
of increasing regimen intensity, for example, need to be
weighed against the risk of increased toxicity and may differ
for various histologies [7]. The use of post-transplantation
maintenance or consolidation has been validated in several
indications and has been previously reviewed in this journal
[8]. More recently, signiﬁcant advances in the treatment
of hematological malignancies have beenmade in the ﬁeld of
immunotherapy [9-14]. This includes adoptive transfer ofdgments on page 21.
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ty for Blood and Marrow Transplantation.receptors (CAR) or T cell receptors (TCR) [9-11], as well as the
growing use of antibody-based approaches with checkpoint
inhibitors [12,13]. In this review, we will focus on these
approaches in the context of hematopoietic stem cell
transplantation (HCT).PAVING THE ROAD FOR CARS: CAR-MODIFIED T CELLS
DIRECTED AGAINST CD19 AFTER HIGH-DOSE THERAPY
AND AUTOLOGOUS TRANSPLANTATION
The cluster of differentiation antigen 19 (CD19) is a 95 kD
transmembrane glycoprotein ubiquitously expressed on
B cells from pro-B to mature B cell phenotypes, including all
B cell NHL (B-NHL)/chronic lymphocytic leukemia/small
lymphocytic lymphoma, and B cell acute lymphoblastic
leukemia (B-ALL). CD19 is not expressed on other hemato-
poietic or organ cell populations. Although targeting CD19
can hypothetically result in B cell aplasia, the clinical expe-
rience with the anti-CD20 monoclonal antibody rituximab
has shown that this does not result in severe consequences.
Thus, CD19 serves as an acceptable tumor antigen to target
for cellular therapy. Genetically engineered recombinant TCR
directed against a speciﬁc tumor antigen (CARs) can recog-
nize and lyse tumor targets. Although most of the clinical
experience of targeting CD19 with CAR-modiﬁed T cells
(19-CAR-T) to date has been reported in patients with acute
lymphoblastic leukemia [15-20], the present section will
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lymphocytic leukemia/small lymphocytic lymphoma.
The initial CAR constructs consisted of an antigen recog-
nizing single chain variable fragment extracellular domain
from an antibody with a transmembrane link to a functional
CD3z intracellular signaling domain [21]. Although this
initial design demonstrated T cell effector function, prolifer-
ation and expansion were not achieved until second-signal
transmembrane costimulatory domains were constructed
in later generation design [22]. This translated into improved
antitumor efﬁcacy in early animal models compared with
ﬁrst generation constructs [23]. The clinical experience of
19-CAR-T for B-NHL reviewed in this manuscript will
largely focus on second-generation 19-CAR-T constructs with
TCR/CD3 signal 1 coupled to signal 2 with either CD28,
or 4-1BB.
Clinical Studies: 19-CAR-T for B-NHL
The ﬁrst clinical experience in 19-CAR-T for patients
with follicular lymphoma (FL, n ¼ 2) and diffuse large B cell
lymphoma (DLBCL, n ¼ 2) was from the City of Hope with a
ﬁrst-generation construct [24]. Both DLBCL patients received
19-CAR-T 1 month after high-dose therapy and ASCT and 1 of
2 remained free of progression at the time of publication. The
2 patients with FL progressed after therapy. Signiﬁcant
toxicity was not observed and 19-CAR-T failed to persist, with
only 1 of 4 patients demonstrating peripheral 19-CAR-T
persistence at 1 week with this ﬁrst-generation construct,
despite IL-2 being exogenously administered in the 2 FL
patients.
The ﬁrst case report of a second-generation 19-CAR-T
incorporating a CD28 costimulatory domain was of a patient
with FL treated along with exogenous IL-2 at the National
Cancer Institute (NCI) [25]. The patient experienced a
partial remission (PR) lasting approximately 10 months and
19-CAR-T persistence for > 6 months. More recently, the NCI
group updated its prospective experience of 19-CAR-T with
CD28 costimulation for refractory B-NHL preceded by lym-
phodepleting chemotherapy consisting of cyclophospha-
mide 60 mg/kg to 120 mg/kg and ﬂudarabine at a total dose
of 125 mg/m2 [26]. Six of 7 patients with DLBCL responded
with either a complete remission (CR) or PR and all 6 patients
with indolent B-NHL responded (PR or CR). The longest
responses were 1 and 2 years for DLBCL and indolent B-NHL,
respectively. The 19-CAR-T expansion peaked from 7 to
17 days. The investigators lowered the dose of 19-CAR-T from
5  106/kg to 1  106/kg because of toxicity, most notably
cytokine release syndrome (CRS). Thirteen of 15 patients
experienced  grade 3 toxicity, predominately with mani-
festations of CRS. In a sequential study presented at the
American Society of Hematology meeting in 2014, the NCI
investigators studied lower dose chemotherapy (cyclophos-
phamide 900 mg/m2 and ﬂudarabine 90 mg/m2) and noted
less toxicity related to severe CRS, but there were too few
patients to assess its impact on disease efﬁcacy [27].
A group from the University of Pennsylvania recently
presented interim results of their phase 2a study treating
chemorefractory FL, mantle cell lymphoma (MCL), and DLBCL
patients with 19-CAR-T at the 2015 American Society of
Clinical Oncology (ASCO) meeting [28]. The construct of
their second-generation 19-CAR-T incorporates a 4-1BB
costimulatory transmembrane domain. Patients were
treated with variable lymphodepleting chemotherapy before
administration of 19-CAR-T on study. Of 12 evaluable treated
patients with DLBCL, 2 patients had a CR and 4 had a PR to19-CAR-T for an overall response rate of 50%. The longest
responder is in continued remission > 1 year after 19-CAR-T.
All 7 patients with FL responded, with the longest remission
being > 1 year after treatment, whereas 1 of 2 patients with
MCL experienced a response with < 2 months of follow-up.
The investigators observed 12 nonhematologic toxic
events  grade 3, with 4 of these events related to CRS or
neurotoxicity.
The Fred Hutchinson Cancer Research Center group
recently presented an update at ASCO 2015 of 19-CAR-T with
4-1BB costimulation for refractory B cell malignancies [29].
Their study is unique in that the 19-CAR-T were composed of
a ﬁxed 1:1 ratio of CD8þ T central memory cells to CD4þ
Tcells based on encouraging preclinical data [30]. Seven of 13
B-NHL patients responded (CR, n ¼ 1; PR n ¼ 6) with no
episodes of severe CRS observed. Clinical responses corre-
lated to peak and persistence of 19-CAR-T in this interim
analysis.
Lastly, investigators from Memorial Sloan Kettering
Cancer Center are currently testing 19-CAR-T in consolida-
tion for high-risk relapsed/refractory DLBCL/aggressive
histology B-NHL in partial chemosensitive remission after a
high-dose therapy ASCT (NCT01840566) [31]. The rationale
for this study is administering the cellular immune therapy
in a lymphoablative setting immediately after high-dose
therapy ASCT (2 and 3 days after stem cell reinfusion) for
potential optimization of 19-CAR-T expansion and efﬁcacy.
The 19-CAR-T utilized by this group includes a CD28 cos-
timulatory molecule. An interim update presented at the
2015 ASCO meeting revealed 4 of 10 evaluable patients in
continuous remission at a median of 14 months after study
treatment and up to nearly 2 years in 2 patients [31].
Although this group has previously reported peak C-reactive
protein to correlate with CRS, this correlation was not
observed in the ﬁrst 11 patients. All but 1 patient developed
fevers, as expected, in neutropenic nadir. The most
common  grade 3 toxicity was reversible neurotoxicity in 7
of 11 patients, which the investigators attributed to CRS. The
study is ongoing and expanding at the ﬁrst dose level of
5  106/kg 19-CAR-T.
Limitations and Future Directions
Despite encouraging data, 19-CAR-T therapy for
B-NHL has not matched the extremely impressive activity
of this modality in B-ALL, wherein the vast majority of
patients achieve CR [15,18]. Whether this is due to micro-
environmental phenotypic differences (marrow versus
nodal-based disease) or other factors between B-ALL and
B-NHL remains highly speculative. As outlined above, the 2
major toxicities of 19-CAR-T therapy include CRS and
neurologic manifestations including but not limited to sei-
zures, seizure-like activity, focal motor deﬁcits, aphasia, and
global encephalopathy [32]. Strategies being developed to
circumnavigate or treat these toxicities include the use of
anti-IL-6 receptor blockade [15] and engineering suicide
genetic elements to “turn-off” the activated cellular product
when toxicity is observed [33]. The goal will be to abrogate
toxicity without ablation of the cellular therapy, for which
corticosteroids currently serve in severe and recalcitrant
toxicity. Future investigation toward improvement in
19-CAR-T efﬁcacy for B-NHL may involve further cos-
timulatory elements and/or lymphoproliferative cytokine
genes engineered into the 19-CAR-T product [34]. Addition-
ally, combinatorial antigen speciﬁcity warrants clinical
investigation [35]. Lastly, the potential for immune
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to be investigated and has rationale, especially considering
phenotypic changes once the cellular product is activated
[36].
CHECKPOINT BLOCKADE IN TRANSPLANTATION
Immune checkpoints are signaling pathways used to
modulate the host’s immune response and are involved in
the normal regulation of immunity and establishment of
tolerance. However, those pathways can be usurped by ma-
lignant cells to evade immune surveillance. The recognition
of this phenomenon has allowed the development of
checkpoint blockade, a strategy through which key check-
point pathways are interrupted or stimulated in an attempt
to effect therapeutic antitumor activity. At present, the 2
principal checkpoint pathways being targeted in oncology
are the cytotoxic T lymphocyte associated protein 4 (CTLA-4)
and programmed death 1 (PD-1) pathways. The biology of
those pathways has been reviewed elsewhere [37-39].
Through monoclonal antibodies (mAbs) directed against
the receptors or ligands involved in those pathways, the
tumor-induced down-regulation of T cell function can be
reversed and clinically effective antitumor activity can ensue.
Checkpoint blockade therapy (CBT) has already yielded
paradigm-changing results in solid tumor treatments, espe-
cially in melanoma, lung cancer, and renal cell cancer, among
others [37-44]. Hematologic malignancies are also a very
tempting target for CBT [12,13]. Indeed, those tumors are
known to be curable in a subset of patients through alloge-
neic (allo) HCT, which relies principally on immune-based
tumor eradication. Early clinical trials of PD-1 blockade
using the mAb pidilizumab suggested activity in lymphoid
malignancies [45], further supported by the encouraging
responses in a phase 2 trial of rituximab þ pidilizumab in
follicular lymphoma [46]. A phase 1 study of the antieCTLA-4
mAb ipilimumab in lymphoma also demonstrated that this
agent could yield durable responses [47]. More recently,
larger phase 1 studies using 2 different PD-1 mAbs, nivolu-
mab and pembrolizumab, have tested this strategy across
several hematologic malignancies. The ﬁrst study tested the
safety and efﬁcacy of nivolumab in patients with relapsed or
refractory (R/R) MM, NHL, and classical HL. The second study
(KEYNOTE-013) tested pembrolizumab in R/R myelodys-
plastic syndromes, MM, NHL, and HL. Preliminary results of
both studies have been reported [48,49]. In both trials, HL
was included based on the frequent ampliﬁcation of genetic
material at 9p24, which results in the over-expression of the
PD-1 ligands, PD-L1 and PD-L2 [50]. This and other mecha-
nisms result in a very high frequency of PD-L1/PD-L2
expression on the surface of the HL tumor cell surface [51],
suggesting that HL is a uniquely vulnerable target for PD-1
blockade. The clinical results to date have validated their
scientiﬁc underpinning, with overall response rates of 87%
with nivolumab and 65% with pembrolizumab. Moreover,
the responses appear durable, with a median duration not
reached in the nivolumab study after 86 weeks of follow-up.
The activity of nivolumab in other hematologic malignancies
was quite variable, with response rates of 36% to 40% noted in
FL, DLBCL, and T cell lymphoma, in contrast to MM where
there were no objective responses [52,53]. Results of pem-
brolizumab outside of HL have not yet been reported.
CBT in ASCT
There is now a tremendous amount of interest and
activity around CBT in hematologic malignancies; many ofthe trials in progress or in planning target patients with R/R
disease. Yet other settings could possibly lend themselves
better to the deployment of this strategy. One such setting
is the post-ASCT period. It is characterized by a minimal
residual disease and by a remodeling immune system;
moreover, in the ﬁrst 6 months or so after transplantation,
there is a relative dominance of the lymphocyte subsets that
are the likely targets of PD-1 blockade [54,55]. CBTafter ASCT
may, therefore, have beneﬁts beyond what it can achieve in
R/R disease. This hypothesis was ﬁrst tested in an interna-
tional phase 2 trial of the antiePD-1 antibody pidilizumab
administered to patients with DLBCL after ASCT [56]. In this
trial, patients received 3 doses of pidilizumab. The 18-month
progression-free survival (PFS) among the 66 eligible
patients was 72%, which met the study’s primary endpoint.
Notably, the 18-month PFS was 70% among the 24 patients
who had a positive positron emission tomography scan after
pre-ASCT salvage therapy, which is now known to be a high-
risk feature in patients undergoing ASCT [57,58]. These
results compared favorably to the 52% PFS in a historical
control population. Also encouraging was the response rate
of 51% to pidilizumab in patients who had measurable dis-
ease after ASCT (with a 34% CR rate). This study, although not
deﬁnitive based on its single-arm phase 2 design, does lend
support to the idea that PD-1 blockade after ASCT may
have useful activity. Studies are currently underway testing
post-ASCT PD-1 blockade in patients with HL or DLBCL
(NCT02362997) and MM (NCT02331368).
CBT after Allogeneic Stem Cell Transplantation
In the case of alloHCT, the goal is to engage a grafted
immune system to cure R/R hematologic malignancies, but
the treatment is associated both with a high relapse risk and
with signiﬁcant toxicity. Immune checkpoint pathways may
be used as a mechanism of tumor survival after trans-
plantation [59,60]. Therefore, the use of CBT after alloHCT
could, in theory, potentiate the salutary graft-versus-tumor
effect and decrease the risk of relapse. If so, CBT could be
used in patients with post-alloHCT relapse or in those at
particular high risk of post-transplantation relapse. The
major concern with the use of CBT after alloHCT is the pos-
sibility that it could unleash severe graft-versus-host disease
(GVHD), which has tempered enthusiasm for conducting CBT
studies in allografted patients. Nonetheless, 2 clinical trials
have already been performed with CTLA-4 blockade and
provide a useful foundation on which future trials may be
built. The ﬁrst was a phase 1 study of ipilimumab adminis-
tered in a single dose to patients with relapsed hematologic
malignancies after alloHCT [61]. Most importantly, this
treatment appeared safe, which is, as mentioned above, a
critical concern for post-alloHCT CBT. Speciﬁcally, with 29
patients treated up to a dose of 3.0 mg/kg, there was no
severe GVHD, no dose-limiting toxicity, and only 3 related
grade 3 or 4 events. Not only was the safety proﬁle favorable,
but there was also some evidence of efﬁcacy: 2 patients with
HL achieved a CR and 1 patient with MCL achieved a PR.
Building on those results, a phase 1b trial (NCT01822509) is
currently underway testing repeated doses of ipilimumab in
this setting (4 doses every 3 weeks, followed bymaintenance
treatment every 12 weeks). Preliminary results have been
reported [62]. At the time of last analysis, 28 patients had
been treated, 26 of whom were evaluable for response.
Among those, 27% had an objective response. Notably, there
were 4 CRs among 12 patients with relapsed acute myeloid
leukemia. All responses occurred at the 10-mg/kg dose level.
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toxicity, including grade 3 GVHD and 2 severe immune-
related adverse events. Overall, these preliminary results
suggest that CBT may be feasible and effective after alloge-
neic transplantation, although additional work is needed to
clarify the optimal dose and schedule. Planned studies will
also examine the safety and efﬁcacy of PD-1 blockade in this
setting. In general, PD-1 blockade has been more extensively
tested in hematologic malignancies than CTLA-4 blockade
has, after the results in solid tumors where PD-1 blockade is
associated with a better ratio of efﬁcacy to toxicity. However,
the post-alloHCT setting could be different, as preclinical
studies in murine models have raised the possibility that
blocking PD-L1 could result in signiﬁcant GVHD [63].
Also relevant to alloHCT is the question of whether PD-1
blockade is safe before transplantation. Indeed, because anti-
PD1 mAbs appear to have a long tissue half-life, they may
continue to exert an effect in patients who proceed to
alloHCT after PD-1 blockade, which could theoretically
improve the efﬁcacy of HCT (through enhanced graft-versus-
tumor) or increase its toxicity (by increasing the incidence or
severity of GVHD and other immune-related toxicities). It
will be very important to carefully describe the outcome of
those patients as we accumulate experience in this domain.
Future Directions
Checkpoint blockade has already transformed the treat-
ment of several solid tumors and may do the same in certain
hematologic malignancies, such as HL. Much remains to be
elucidated about which tumors to target, which checkpoint
pathways to disrupt, which other types of treatment to best
combine with CBT, and in which setting to most safely and
effectively use this modality. Stem cell transplantation, both
autologous and allogeneic, may provide a fertile ground for
CBT, as in both cases the immune landscape may be partic-
ularly favorable for this type of intervention. Ongoing and
future studies will shed further light on this question, in the
ultimate hope of increasing the cure rates for patients with
hematologic neoplasms.
ADOPTIVE CELL THERAPY AND CHECKPOINT INHIBITORS
IN MULTIPLE MYELOMA
ASCT is considered a standard treatment for patients
with MM [2,6]. Although clinical outcomes have improved
signiﬁcantly with ASCT as well as the introduction of
immunomodulatory drugs (thalidomide, lenalidomide, and
pomalidomide) and proteasome inhibitors (bortezomib and
carﬁlzomib), most patients are not cured. As noted above, the
role of post-transplantation maintenance in MM has been
reviewed previously [8]. In this section, we will review
approaches to target tumor antigens expressed in MM,
including adoptive cell therapy, as well the recent studies on
checkpoint inhibitors.
Targeting Tumor Antigens in MM
Humoral and cellular immune responses to antigens
expressed on myeloma cells have been identiﬁed in patients
with MM. These include Wilm’s tumor 1 and cancer-testis
antigens, such as melanoma-associated antigen (MAGE) 3,
MAGE-C2, MAGE-C1/CT7, SSX2 and NY-ESO-1 [64-69].
Although it had been postulated that immune deﬁciency
after HCT would prevent the generation of effective anti-
tumor immunity, preclinical studies as well as clinical trials
have shown that lymphopenic state early after HCT may
actually provide an opportunity to skew the recoveringimmune repertoire towards tumor-speciﬁc antigens [70-73].
In preclinical mouse models, irradiation of mice followed by
lymphocyte infusion and immunization against tumor anti-
gens resulted in signiﬁcant increases in T cell responses to
these antigens and tumor eradication [70]. This study also
demonstrated a critical window for optimal responses where
both the timing of immunization and lymphocyte infusion in
the irradiated host were crucial. These results are further
supported by clinical trials in which patients with MM
underwent ASCT followed by lymphocyte infusion and
immunization [71,72]. In the more recent study, 54 patients
with MM underwent ASCT followed by ex vivoestimulated
autologous Tcells at day 2 after transplantation [71]. Twenty-
eight patients who were HLA-A0201 underwent immuniza-
tion before and after transplantation with a multipeptide
vaccine against human telomerase reverse transcriptase and
survivin. Thirty-six percent of immunized patients devel-
oped immune responses to the tumor antigen vaccine.
Additional studies of tumor immunization are ongoing in
patients with MM undergoing ASCT. In 1 phase 1 trial, for
example, patients with MM undergoing ASCT are being
vaccinated with dendritic cells electroporated with CT7,
MAGE-A3, and Wilm’s tumor 1 mRNA (NCT01995708).
Gene-modiﬁed T Cells in MM
As noted above, dramatic results have been reported
with the use of CAR T cells in ALL and promising results have
also been seen in patients with NHL. A recent case report
described the use of CD19 CAR Tcells after a second ASCT in a
patient with MM [74]. The patient sustained a CR without
evidence of recurrence at 12 months. These results are
interesting given the extremely low expression of CD19 on
the patient’s neoplastic plasma cells. It should be noted,
however, that the response needs to be viewed in context of
the fact that the patient received the cells after ASCT.
Furthermore, preliminary results of this trial (NCT02135406)
presented at ASCO in 2015 suggest this patient may be a
unique responder or, at least, the best responder [75].
In contrast, the recently reported study of T cells geneti-
cally modiﬁed to express a TCR speciﬁc for a peptide shared
by the cancer-testis antigens NY-ESO-1 and LAGE-1 showed
more consistent positive responses [76]. Twenty MM
patients received engineered T cells 2 days after ASCT.
Clinical responses were seen in 16 of 20 patients (80%), with
a median PFS of 19.1 months. The authors also demonstrated
that engineered T cells trafﬁcked to marrow and showed
persistence that correlated with clinical activity. One of the
known limitations of TCRs compared to CARs is the fact that
they are HLA restricted and can, therefore, only be used in
the patients with a speciﬁc HLA, unlike CARs, which can be
used universally. Other targets under investigation with CAR
T cells or NK cells include CS1, a cell surface glycoprotein
highly expressed on the surface of myeloma cells [77,78], as
well as CD38, CD138, B cell maturation antigen, and kappa
light chain [79].
Checkpoint Inhibitors in MM
PD-1 and its ligands have been shown to be broadly
expressed in the myeloma microenvironment and pre-
clinical data supporting the use of checkpoint inhibitors in
MM have led to studies of antiePD-1 antibodies in MM [80-
82]. However, preliminary results of a phase 1 study of
nivolumab in patients with R/R lymphoid malignancies
have been relatively disappointing in MM compared with
studies in lymphoma [53]. Recent data suggest that other
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in MM, explaining the lack of response to these agents [83].
Future Directions
The treatment of MM is evolving rapidly with the intro-
duction of novel agents and combinations. Nevertheless,
despite increased rates and depth of response, most patients
will not be cured. Early results with new immunotherapy
approaches, including CARs and TCRs, as well cancer vaccine
approaches, offer encouraging results that will require vali-
dation in larger prospective trials. The potential role of
checkpoint inhibitors in MM remains under investigation
and their full beneﬁt may require combination studies.
CONCLUSIONS
ASCT remains a curative treatment for many patients
with hematologic malignancies. Recent studies seeking to
enhance immune responses either through the use of CAR
T cells targeting CD19 or checkpoint inhibitors have shown
remarkable results in patients with leukemia and lym-
phoma in the nontransplantation setting. These approaches
have served as a bridge to transplantation or have been
used as salvage for patients who relapse or progress after
transplantation. Ongoing studies are examining the role of
combining these therapies with stem cell transplantation to
further improve outcomes in patients with lymphoma and
MM.
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